Patel, Dhavalkumar (2015) Th17 cells in human immunity and autoimmune disease pathogenesis. Th17 cells in human immunity and autoimmune disease pathogenesis, 43 (6). pp. 1040-1051. ISSN 10747613

Abstract

Largely driven by human genetics and use of therapeutic principles, tremendous strides have been made in the understanding Th17 cells in human immunity and autoimmune disease pathogenesis. The Th17 pathway has been linked by genome wide association studies to multiple autoimmune diseases. Identification of the genetic causes of primary immunodeficiency diseases revealed that Th17 cells have a critically important role in host immunity to mucocutaneous candida infections and staphylococcus aureus. Therapeutic interventions with inhibitors of the different components of the pathway such as IL-12/23 (ustekinumab, briakinumab), IL-23 (guselkumab, tildrakizumab, BI-655066, AMG139 and LY3074828), IL-17A (secukinumab, ixekizumab, CNTO-6785 and CJM112), and IL-17RA (brodalumab) have variably beneficial effects in psoriasis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis, and multiple sclerosis. In summary, Th17 cells play an important role in protective immunity against candida albicans and to a lesser degree staphylococcus aureus, and are pathogenic in many autoimmune diseases.

Item Type:	Article
Date Deposited:	03 May 2016 23:45
Last Modified:	03 May 2016 23:45
URI:	https://oak.novartis.com/id/eprint/27617